about
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.An update for Richter syndrome - new directions and developments.Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOPImpact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by ageA retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLIbrutinib for the treatment of Bing-Neel syndrome: a multicenter studyAssessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective StrategyOutcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalAnother disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomasThe efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaA phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCLEfficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphomaStand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicityInduction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practicePrognostication in Richter syndrome: context is everythingEfficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
P50
Q38600671-BB9824A7-8AD8-406D-8C06-8C7BE7CE0BCAQ38691261-30877819-182A-4D03-819D-2B2593D9A138Q48234238-8F978027-2AD6-4B7D-A637-2A8274338719Q48362683-55FE3510-072F-41FC-AC8F-F798AC1A2F01Q52688658-DB3DDFD1-4991-46CC-959C-131CF0BA02B8Q64110280-7098DFAC-3BE0-4DDC-8D31-3CF469BDB4B0Q64114828-13982147-4ECB-479F-A994-4FEAFF13525EQ64290233-19FA6FBB-7D55-4E09-A059-2479E353F25CQ90316799-A585DBA3-8B9F-4864-9771-38D648F00DF5Q90538040-EF4B0603-D875-4F49-8B99-D3318E0EA6AFQ90788040-07F47A47-3DAC-4D19-9B87-672AE0E364F9Q91078612-15C97D91-8DEC-426E-A8C9-1F34AF697C66Q91085985-52185D02-A448-4375-8723-F9BDDEA7EB59Q92441394-4541371F-DB45-41C3-9980-0E29C6121A33Q92923883-37E1BD26-D49E-487A-A928-FA835758E531Q92923917-F6331CB0-D435-4CBD-B1DA-3F270E909911Q93044027-30AB780B-CDE9-44CD-9441-2C2F3B7D15F8Q95269419-C50DEBD0-D4FB-479F-8313-70A7A88A8314Q95404520-1D7A553A-B168-44A1-AE28-2B78F20F167E
P50
description
researcher
@en
wetenschapper
@nl
name
Toby A Eyre
@en
Toby A Eyre
@nl
type
label
Toby A Eyre
@en
Toby A Eyre
@nl
prefLabel
Toby A Eyre
@en
Toby A Eyre
@nl
P31
P496
0000-0002-6631-9749